Research Article
Combination Model of Thyrotrophin Receptor Antibody and Volumetric Orbital Apex Crowding Index as an Indicator of Dysthyroid Optic Neuropathy
Table 1
Comparison of basic demographic data and clinical findings between TED patients with and without DON.
| | Parameter | DON group (16 eyes) | TED group (without DON) (34 eyes) | |
| | Demographic | | | | | Male | 8 (50.0%) | 16 (47.1%) | 0.870 | | Right eye | 10 (62.5%) | 15 (44.1%) | 0.225 | | Age (years) | 49.94 (11.48) | 49.91 (9.29) | 0.994 | | Clinical history | | | | | Chief complaint | | | | | Exophthalmos/vision loss/others | 2/11/3 | 16/11/7 | 0.137 | | History of complaint (months) | 7.3 (8.8) | 9.4 (6.8) | 0.480 | | Type of thyroid disease | | | | | Hyperthyroidism/euthyroid | 16/0 | 32/2 | / | | Antithyroid therapy | | | | | ATD/I131 | 11/5 | 25/9 | 0.772 | | Thyroid function at the first visit | | | | | Hyperthyroidism/euthyroid/hypothyroidism | 3/4/9 | 17/9/8 | 0.103 | | History of thyroid dysfunction (months) | 29.2 (28.6) | 31.19 (49.4) | 0.920 | | BCVA (logMAR) | 0.584 (0.591) | -0.018 (0.055) | 0.006 | | Degree of exophthalmos (mm) | 21.6 (4.1) | 19.6 (2.7) | 0.213 | | Clinical activity | | | | | CAS (0–7) | 4.17 (1.99) | 2.42 (1.14) | 0.026 | | Active () | 12 (75%) | 13 (38.2%) | 0.106 | | Thyroid hormone and antibodies | | | | | FT3 (pmol/L) | 4.25 (1.25) | 6.25 (2.49) | 0.033 | | FT4 (pmol/L) | 12.8 (4.4) | 17.4 (4.9) | 0.029 | | TSH (mIU/L) | 20.97 (33.43) | 4.13 (7.75) | 0.134 | | TGA (IU/mL) | 1144 (1452) | 578 (1237) | 0.365 | | TPOA (IU/mL) | 176 (173) | 176 (191) | 0.998 | | TRAb (IU/L) | 27.0 (14.7) | 14.1 (11.8) | 0.009 | | Uptake ratio of extraocular muscles | | | | | Medial rectus | 12.7 (4.2) | 10.4 (1.7) | 0.070 | | Superior rectus | 10.2 (3.6) | 8.0 (2.3) | 0.025 | | Inferior rectus | 11.2 (4.0) | 10.4 (2.2) | 0.608 | | Lateral rectus | 8.4 (3.6) | 8.4 (2.0) | 0.506 | | Mean of four recti | 10.62 (3.64) | 9.3 (1.3) | 0.187 | | VACI | 6.05 (3.16) | 2.42 (1.14) | 0.001 |
|
|
, . DON: dysthyroid optic neuropathy; TED: thyroid eye disease; ATD: antithyroid drug; CAS: clinical activity score (of TED); FT3: free triiodothyronine (reference range, 3.1–6.8); FT4: free thyroxine (reference range, 12–22); TSH: thyroid-stimulating hormone (reference range, 0.27–4.20); TGA: thyroglobulin antibody (reference range, 0–115); TPOA: thyroid peroxidase antibody (reference range, 0–34); TRAb: thyrotrophin receptor antibody (reference range, 0–1.75); VACI: volumetric orbital apex crowding index. |
